Richard Kenney

Chief Medical Officer

Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (1)

Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment. Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination. Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease. Conclusions: The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.

Year:

2026

Collaborators (6)

Stephanie L. Graff

Brown University

UNITED STATES
View details

Keith Knutson

Mayo Clinic Florida

UNITED STATES
View details

Priyanka Sharma

Associate Professor

University of Kansas Medical Center

UNITED STATES
View details

Nadine Norton

Associate Professor

Mayo Clinic Florida

UNITED STATES
View details

Joseph A. Sparano

Chief, Division of Hematology/Oncology; Deputy Director, Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Aziza Nassar

Consultant/Professor of Pathology

Medical University of South Carolina

UNITED STATES
View details